Your session is about to expire
← Back to Search
Lenalidomide for Mild Cognitive Impairment (MCLENA-1 Trial)
MCLENA-1 Trial Summary
This trial will investigate whether the immunomodulator lenalidomide can help treat Alzheimer's by reducing inflammation.
MCLENA-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMCLENA-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 3 trial • 205 Patients • NCT00179621MCLENA-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with multiple myeloma before.I have not had a heart attack or unstable heart disease in the past year.I currently have active cancer.My thyroid condition is stable, treated for at least 6 months.I can take pills by mouth.I cannot or do not want to have MRI and PET scans.I can attend all required study visits.I haven't had a brain or mental health issue in the last 3 years that could lead to memory loss.I have had or currently have blood clots.I have a serious blood or clotting disorder.You have a Hachinski ischemic score of 4 or lower.I have been on a stable dose of medication for memory problems for at least 90 days.I have a low neutrophil count or a history of it.My brain scan shows no significant issues contributing to dementia.Your score on the geriatric depression scale is 10 or lower.You have been diagnosed with a major psychiatric disorder according to the DSM IV criteria.I have been hospitalized more than twice in the past year for severe lung problems.I haven't taken any experimental drugs recently.You have a history of drinking too much alcohol or using drugs.My high blood pressure is not well-managed.My prostate cancer is stable, as confirmed by my doctor.I am between 50 and 89 years old.I have sleep apnea that has not been treated.I have been diagnosed with mild memory loss and my mental state exam score is between 22-28.I do not have serious liver or kidney disease.I am a woman who could become pregnant.I am a woman who has been menopausal for at least 2 years or am surgically sterile.Your medical records show that you have amnestic mild cognitive impairment.
- Group 1: Lenalidomide
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the enrollment criteria for this trial restricted to individuals over 25 years of age?
"According to the requirements for enrollment, participants must be over 50 years old and no older than 89."
What therapeutic applications is Lenalidomide 10 mg typically utilized for?
"Lenalidomide 10 mg is employed to manage multiple myeloma, relapsed/refractory lymphoma, chronic lymphocytic leukemia and some other diseases after two antecedent systemic chemotherapy regimens."
Could you please detail the scope of previous research involving Lenalidomide 10 mg?
"Lenalidomide 10 mg was initially studied in 2004 by the Midwest Center for Hematology Oncology. To date, 18659 trials have been finalized, with 268 active and recruiting studies taking place across Las Vegas, Nevada."
What is the highest amount of individuals partaking in this clinical research?
"That's correct. Based on the clinicaltrials.gov listing, this clinical trial is in need of additional participants and was first posted on July 22nd 2020. The most recent update came out April 14th 2022 with a target goal of 30 patients across 2 research centres."
Has the Federal Drug Administration sanctioned Lenalidomide 10 mg for use?
"Our team has determined that lenalidomide 10 mg is relatively safe, as it received a score of 2. This assessment was based on the fact that this drug is in Phase 2 trials where there are some supporting safety studies but no evidence for efficacy yet."
Who is the ideal cohort for participating in this research?
"This investigation is open to 30 adults with senile plaques aged between 50 and 89. Eligibility necessitates that the participants are male or female outpatients, have a documented Mini Mental State Exam (MMSE) score of 22-28, be able to take oral medicines, have an Hachinski Ischemic Score ≤4 on their Geriatric Depression Scale test which must also rate below 10, possess functional vision & hearing aptitudes for study procedures; those taking cholinesterase inhibitors/memantine must remain on stable doses from at least 90 days before commencement (Week 00), and cannot exhibit intolerance or lack of"
Is the patient enrollment for this trial still ongoing?
"As per clinicaltrials.gov, this trial is actively enrolling potential participants. This project was initially created on July 22nd 2020 and most recently updated on April 14th 2022."
Share this study with friends
Copy Link
Messenger